<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104150">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01844661</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT2008-000364-16</org_study_id>
    <nct_id>NCT01844661</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Repeated Infusion of CELYVIR in Children and Adults With Metastatic and Refractory Tumors.</brief_title>
  <official_title>Phase 1 Trial of Celyvir in Children and Adults With Metastatic and Refractory Solid Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Infantil Universitario Niño Jesús, Madrid, Spain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Infantil Universitario Niño Jesús, Madrid, Spain</source>
  <oversight_info>
    <authority>Spain: Spanish Agency for Medicine and Health Products</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will evaluate the safety of weekly infusions (n=6) of CELYVIR in children
      and adults with metastatic and refractory solid tumors. CELYVIR consists in bone
      marrow-derived autologous mesenchymal stem cells (MSCs) infected with ICOVIR5, an oncolytic
      adenovirus. In addition to data on toxicities the investigators will evaluate clinical
      response.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Adverse effects after intravenous infusions</measure>
    <time_frame>48 hours after each infusion</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>We will record any sign or symptom that could be related to the infusion of Celyvir.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome</measure>
    <time_frame>Up to 2 months after the last infusion</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical outcome will be labelled as complete response, partial response, stable disease or disease progression.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Children</condition>
  <condition>Solid Tumors</condition>
  <condition>Metastases</condition>
  <arm_group>
    <arm_group_label>CELYVIR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will received weekly (n=6) IV infusion of Celyvir.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CELYVIR</intervention_name>
    <arm_group_label>CELYVIR</arm_group_label>
    <other_name>Bone marrow-derived autologous mesenchymal stem cells infected with ICOVIR5, an oncolytic adenovirus.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children: Up to 18 yrs. Refractory to at least 2 previous therapy lines. Life
             expectancy more than 6 months. Measurable disease.

          -  Adults: 18-75 yrs. Refractory to at least 2 previous therapy lines. ECOG (Eastern
             Cooperative Oncology Group) &lt;2. Measurable disease.

        Exclusion Criteria:

          -  Pregnancy.

          -  Central Nervous System metastasis.

          -  Experimental therapy during the previous month.

          -  Chemotherapy less than 3 weeks previous.

          -  Any organ functionally impaired.

          -  Concurrent infectious disease.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel Ramírez, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Niño Jesús</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manuel Ramirez, MD PhD</last_name>
    <phone>+34915035938</phone>
    <email>mramirezo.hnjs@salud.madrid.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Niño Jesús</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Ramirez, MD PhD</last_name>
      <phone>+34915035938</phone>
      <email>mramirezo.hnjs@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Manuel Ramirez, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 1, 2013</lastchanged_date>
  <firstreceived_date>April 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Infantil Universitario Niño Jesús, Madrid, Spain</investigator_affiliation>
    <investigator_full_name>Manuel Ramírez, MD PhD</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Mesenchymal stem cells</keyword>
  <keyword>Oncolytic adenovirus</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
